Latest Earnings Results: Q3 '26
Estimated EPS
-$0.18
Reported EPS
-$0.25
Surprise
-37.3%
Estimated Rev
$18.34M
Reported Rev
$18.42M
Surprise
+0.42%
• Reported GAAP EPS of -$0.25 up 19.35% YoY • Reported revenue of $18.42M up 6.84% YoY • Exagen reiterated full-year 2026 revenue guidance of $72M to $75M and said its myositis offering remains on track to launch early in 2027.
Bullish Takeaway
Exagen's Q3 revenue and trailing-twelve-month ASP increased, nine-month net loss and adjusted EBITDA loss were lower than 2025, and the company remains on track to launch myositis early in 2027.
Bearish Takeaway
Exagen reported higher Q3 operating expenses and operating loss than Q3 2025, cash of $28.09M, and cited reimbursement and coverage delays as business risks.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.19 | -- | -- | N/A |
Q3 '26 | -$0.18 | -$0.25 | -37.30% | MISSED |
Q2 '26 | -$0.19 | -$0.13 | 32.09% | BEAT |
Q1 '26 | -$0.23 | -$0.17 | 26.99% | BEAT |
Q4 '25 | -$0.19 | -$0.20 | -5.43% | MISSED |